By Damian J. Troise and Alex Veiga

Stocks shook off a sluggish start to finish with modest gains Wednesday, nudging the S&P 500 index to an all-time high for the second straight day.

The benchmark index rose 0.2% after spending much of the day drifting between small gains and losses. About 54% of the stocks in the index rose, with communications, financial and health care companies driving the bulk of the gains. A pullback in technology stocks, companies that rely on consumer spending and elsewhere kept the market's gains in check.

Treasury yields continued to head mostly higher, a sign of growing confidence in the outlook for the economy. That confidence has also been pushing stocks higher in recent weeks as traders hope coronavirus vaccines will start driving a stronger economic recovery. Investors were not deterred by new data Wednesday showing that hiring by U.S. companies slowed last month.

“The biggest thing about the market that we’ve seen the last couple of weeks is (investors) keep trying to sell it, and it still hangs in there,” said J.J. Kinahan, chief strategist at TD Ameritrade.

The S&P 500 rose 6.56 points to 3,669.01. The index is now up about 13.6% for the year. The Dow Jones Industrial Average gained 59.87 points, or 0.2%, to 29,883.79. The tech-heavy Nasdaq composite, which also opened the month with a new record, slipped 5.74 points, or 0.1%, to 12,349.37.

Stocks have been ramping higher in recent weeks as drugmakers make steady progress in developing coronavirus vaccines. The rollout of a vaccine in the U.S. could begin this month, if regulators give their approval.

Pfizer shares rose 3.5% after the drugmaker and BioNTech said they won permission for emergency use of their COVID-19 vaccine in Britain. The vaccine is the world’s first coronavirus shot that’s backed by rigorous science and a major step toward eventually ending the pandemic. The move makes Britain one of the first countries to begin vaccinating its population against the virus. The companies have already asked for approval to begin vaccinations in the U.S. in December.

Moderna is also asking U.S. and European regulators to allow emergency use of its COVID-19 vaccine. Its shares rose 1.4%.

Optimism about vaccine developments have tempered lingering concerns over rising virus cases in the U.S., though worries persist about the economic fallout from new government restrictions on businesses aimed at limiting the spread.

“My farther-out fear for the market is once this vaccine starts to roll out, will it be able to meet these amazing expectations people have for everything getting back to normal?” Kinahan said.

Unemployment remains high as the COVID-19 outbreak widens the gulf between average people and the wealthiest Americans. Payroll processor ADP said Wednesday that its latest survey of private U.S. employers shows they added 307,000 jobs last month. That fell short of Wall Street analysts’ expectations for a gain of 405,000 jobs, according to FactSet.

The report precedes a broader jobs survey from the Labor Department due out Friday. Economists are forecasting that will show employers added about 441,000 jobs in November, down from a gain of 638,000 in October.

Meanwhile, traders are holding out hope that Democrats and Republicans may reach a deal on some amount of economic stimulus for the economy before 2021, though the parties remain divided on the details and the cost.

The Federal Reserve's latest survey of business conditions around the U.S. found economic activity has slowed in some parts of the country as amid a surge in new coronavirus cases. On Wednesday, Federal Reserve Chairman Jerome Powell and Treasury Secretary Steven Mnuchin told lawmakers during a House Financial Services Committee hearing that Congress needs to approve COVID-19 relief funds without further delay.

However, it's looks like most lawmakers are willing to wait until after President-elect Joe Biden takes office, said Ross Mayfield, investment strategy analyst at Baird.

“The problem is, by that point you’re going to have six to 10 more weeks of economic damage,” he said.

Technology stocks, which have been leading the market higher since the pandemic started wreaking havoc on the global economy, helped limit the market's gains Wednesday. Salesforce.com was the biggest decliner in the S&P 500, tumbling 8.5%, after announcing a deal late Tuesday to buy messaging platform Slack for $27.7 billion. Microsoft slipped 0.4%.

Lyft climbed 9.6% after the ride-hailing company posted a smaller loss this quarter and better margins. The news helped boost rival Uber Technologies up 7%.

Treasury yields headed higher, giving banks a boost because they allow them to charge more lucrative interest rates on loans. The yield on the 10-year Treasury rose to 0.96% from 0.92% late Tuesday. JPMorgan Chase rose 1.9% and Citigroup gained 3.1%.

Germany's DAX shed 0.5% and France's CAC 40 was flat. In Britain, the FTSE 100 rose 1.2%. Markets in Asia were mixed.

Updated on December 2, 2020, at 5:21 p.m. ET.

Share:
More In Business
2022 Promises a Mixed Bag of Market Predictions
2021 saw markets continue to be impacted by the onslaught of the coronavirus pandemic -most recently in the form of the Omicron variant- in addition to the global supply chain shortage, and increased inflation. But it wasn't all bad news, as crypto soared throughout the year, and meme stocks continued to have a moment. With the year coming to a close, investors are keeping an eye out to see if they should expect more of the same in the new year. Chris Vecchio, Senior Analyst, at DailyFX tells us what market trends to be on the watch for in 2022.
Under Threaten of Competition, Tesla Held Its Own in 2021
2021 proved to be yet another formidable year for Tesla. In a year that saw electric vehicles carve out their own space in the transportation world, the company made further strides, keeping its spot on top even as new companies threatened competition. Tesla was able to hit the trillion dollar valuation mark, increase vehicle deliveries even as the world grappled with supply chain and delivery issues and sign a major deal with Hertz this year. And of course, you can't talk about Tesla without talking about Elon Musk, CEO and founder of the company, richest man in the world and Time Magazine Person of the Year, who saw plenty of successes in 2021 as well. Al Root, Senior Writer at Barron’s, explains just how good a year it was for Tesla.
U.S. Home Prices Climb 18.4% in October Compared to Last Year
The S&P CoreLogic Case-Shiller 20-city home price index showed an 18.4 percent surge in October as the housing market continues to boom. October's levels are a slight downturn from the roughly 19 percent increase the index saw in September, but come roughly in line with economist expectations. Michael J. Romer, Managing Partner, Romer Debbas joined Wake Up with Cheddar to discuss.
Thousands of U.S. Flights Cancelled Due to Omicron Spike, Labor Shortages
U.S. airlines have canceled more than 6,000 flights since Christmas eve, causing headaches for travelers. Airlines cited staffing shortages amid the omicron outbreak as the primary reason for the interruptions to service. The cancellations come at the busiest time of year for air travel. Steve Shur, President, The Travel Technology Association joined Wake Up with Cheddar to discuss.
Experts Warn Pfizer, Merck COVID-19 Treatments Need Careful Supervision
Dr. Soumi Eachempati, co-founder and CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College, joined Cheddar to breakdown what people should know about the recently FDA-approved emergency use of Merck and Pfizer's COVID-19 treatment pills. He noted that not only do people need to be aware of other medications they are taking that could cause adverse effects if coupled with COVID-19 pill treatments, he also talked about the intense in-take regiment. "The Merck pills are actually about 40 pills over five days. The Pfizer ones are three pills over five days, so people have to be prepared for that because it is a lot of pills you'll have to take to get full value from these drugs," Eachempati told Cheddar.
World's Largest Dispensary Planet 13 Plans Cannabis Consumption Lounge
Adult-use cannabis sales kicked off in Nevada in 2017, but four years later, there isn’t a legal way for the 40 million tourists who visit the state annually to consume. That’s all about to change. Following the passage in June of a bill to legalize consumption lounges, the world’s largest dispensary, Planet 13, is planning a cannabis club as extravagant as Las Vegas. Cheddar’s Chloe Aiello visited the cannabis entertainment complex to find out more.
Load More